HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (30) Citing Articles via Google Scholar Google Scholar Articles by Doan, T. Articles by Massarotti, E. Search for Related Content PubMed PubMed Citation Articles by Doan, T. Articles by Massarotti, E. Social Bookmarking                   What's this?

Rheumatoid Arthritis: An Overview of New and Emerging Therapies

From the Tufts-New England Medical Center, Boston, Massachusetts.

Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disorder characterized by symmetric inflammation of synovial joints leading to progressive erosion of cartilage and bone. The aim of treatment is to mitigate joint destruction, preserve function, and prevent disability. The American College of Rheumatology guidelines for the treatment of RA recommend that newly diagnosed patients with RA begin treatment with disease-modifying antirheumatic drugs (DMARDs) within 3 months of diagnosis. Methotrexate remains the most commonly prescribed DMARD and is the standard by which recent new and emerging therapies are measured. Increasing knowledge regarding the immunologic basis of RA and advances in biotechnology have resulted in new, targeted biological therapies against proinflammatory cytokines that have dramatically changed the treatment paradigm and outcomes of patients with RA. This article reviews the pharmacological rationale underlying RA therapy, with a focus on currently available biological therapies and new therapies in development.

Key Words: Rheumatoid arthritis • biological therapies • cytokines

Address for reprints: Elena Massarotti, MD, 750 Washington Street, NEMC 599, Boston, MA 02111.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. Zapata-Gonzalez, F. Rueda, J. Petriz, P. Domingo, F. Villarroya, J. Diaz-Delfin, M. A. de Madariaga, and J. C. Domingo Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR{gamma}:RXR heterodimers: comparison with other polyunsaturated fatty acids J. Leukoc. Biol., October 1, 2008; 84(4): 1172 - 1182. [Abstract] [Full Text] [PDF]

				Y. Ibold, S. Frauenschuh, C. Kaps, M. Sittinger, J. Ringe, and P. M. Goetz Development of a High-Throughput Screening Assay Based on the 3-Dimensional Pannus Model for Rheumatoid Arthritis J Biomol Screen, October 1, 2007; 12(7): 956 - 965. [Abstract] [PDF]

				C. D. Conrad, K. J. McLaughlin, J. S. Harman, C. Foltz, L. Wieczorek, E. Lightner, and R. L. Wright Chronic Glucocorticoids Increase Hippocampal Vulnerability to Neurotoxicity under Conditions That Produce CA3 Dendritic Retraction But Fail to Impair Spatial Recognition Memory J. Neurosci., August 1, 2007; 27(31): 8278 - 8285. [Abstract] [Full Text] [PDF]

				Y. Nakai, K. Inoue, N. Abe, M. Hatakeyama, K.-y. Ohta, M. Otagiri, Y. Hayashi, and H. Yuasa Functional Characterization of Human Proton-Coupled Folate Transporter/Heme Carrier Protein 1 Heterologously Expressed in Mammalian Cells as a Folate Transporter J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 469 - 476. [Abstract] [Full Text] [PDF]

				S. P Bruce and E. G Boyce Update on Abatacept: A Selective Costimulation Modulator for Rheumatoid Arthritis Ann. Pharmacother., July 1, 2007; 41(7): 1153 - 1162. [Abstract] [Full Text] [PDF]